New Reporting From IntrinsiQ Measures Impact Of Key Events On Oncology Drug Usage

Main Category: Cancer / Oncology
Article Date: 04 Sep 2008 - 4:00 PST

email to a friend   printer friendly   view / write opinions   rate article

IntrinsiQ, LLC, the expert source for clinical oncology insight, launched Event IntelliView, a new analysis tool that quantifies the real-world impact of key events in the lifecycle of medical oncology drugs.

Pharmaceutical research teams can now quickly make sense of vast amounts of product performance data, and see how activities like reporting on clinical findings, regulatory approvals and price changes positively or negatively impact market penetration. This insight gives crucial corporate understanding of what ultimately drives the usage of oncology products and competitive threats that might impact future growth rates.

Event IntelliView standardizes publicly available information on major market activities and ties them directly to IntrinsiQ's real-time, real-world performance data of oncology drug therapies, easily searchable by product and event. This high-level of visibility enables pharmaceutical companies to more accurately predict growth and anticipate potential threats based on how oncologists respond to factors like:

- Dramatic price increases which significantly hindered Velcade's market performance

- A negative FDA opinion for use of Avastin in breast cancer brought negative pressure prior to the ultimate, unexpected regulatory approval

- The wide spectrum of available clinical data drove two distinct inflection points of uptake of Oxaliplatin in colorectal cancer

"Pharmaceutical research teams are under increasing pressure to explain why a drug fared one way or another and how a drug's lifecycle and profit window can be extended," said Brent Clough, IntrinsiQ's CEO. "They now have the ability to show what's at stake and make sound recommendations based on unimpeachable market data."

Available now, Event IntelliView's reporting is updated quarterly.

About IntrinsiQ

IntrinsiQ, LLC is the leading provider of medical oncology workflow solutions and the premier source of US oncology data and analysis. Each month, IntrinsiQ's market leading software application, IntelliDose®, captures the treatment decisions and details from more than 500 oncologists, for more than 19,500 unique patients, and regarding more than 128,000 drug administrations. The IntrinsiQ database is unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. This database is the foundation of products and services that uniquely address the business information needs of pharmaceutical product managers, market researchers and financial analysts.

IntrinsiQ